标题/作者	年份
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention DQ Huang, HB El-Serag, R Loomba Nature Reviews Gastroenterology & Hepatology 18 (4), 223-238	2021
A novel ferroptosis-related gene signature for overall survival prediction in patients with hepatocellular carcinoma J Liang, D Wang, H Lin, X Chen, H Yang, Y Zheng, Y Li International journal of biological sciences 16 (13), 2430	2020
Complications, morbidity and mortality of nonalcoholic fatty liver disease A Mantovani, E Scorletti, A Mosca, A Alisi, CD Byrne, G Targher Metabolism 111, 154170	2020
Targeted therapy for hepatocellular carcinoma A Huang, XR Yang, WY Chung, AR Dennison, J Zhou Signal transduction and targeted therapy 5 (1), 146	2020
Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma A Sharma, JJW Seow, CA Dutertre, R Pai, C Blériot, A Mishra, RMM Wong, ... Cell 183 (2), 377-394. e21	2020
RNA m6A methylation regulates sorafenib resistance in liver cancer through FOXO 3‐mediated autophagy Z Lin, Y Niu, A Wan, D Chen, H Liang, X Chen, L Sun, S Zhan, L Chen, ... The EMBO journal 39 (12), e103181	2020
Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment F Piñero, M Dirchwolf, MG Pessôa Cells 9 (6), 1370	2020
New advances in the diagnosis and management of hepatocellular carcinoma JD Yang, JK Heimbach Bmj 371	2020
Recent progress in treatment of hepatocellular carcinoma Z Chen, H Xie, M Hu, T Huang, Y Hu, N Sang, Y Zhao American journal of cancer research 10 (9), 2993	2020
Prevention of hepatitis B virus–related hepatocellular carcinoma ASF Lok Gastroenterology 127 (5), S303-S309	2004
The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review M Pinter, RK Jain, DG Duda JAMA oncology 7 (1), 113-123	2021
The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis M Chen, CM Wong Molecular cancer 19, 1-12	2020
ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1 Y Chen, Y Zhao, J Chen, C Peng, Y Zhang, R Tong, Q Cheng, B Yang, ... Molecular cancer 19 (1), 1-19	2020
Global trends in incidence rates of primary adult liver cancers: a systematic review and meta-analysis P Dasgupta, C Henshaw, DR Youlden, PJ Clark, JF Aitken, PD Baade Frontiers in oncology 10, 171	2020
Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial S Qin, F Bi, S Gu, Y Bai, Z Chen, Z Wang, J Ying, Y Lu, Z Meng, H Pan, ... Journal of Clinical Oncology 39 (27), 3002-3011	2021
CircRNA hsa_circRNA_104348 promotes hepatocellular carcinoma progression through modulating miR-187-3p/RTKN2 axis and activating Wnt/β-catenin pathway G Huang, M Liang, H Liu, J Huang, P Li, C Wang, Y Zhang, Y Lin, X Jiang Cell death & disease 11 (12), 1065	2020
Targeting cancer-promoting inflammation—have anti-inflammatory therapies come of age? J Hou, M Karin, B Sun Nature reviews Clinical oncology 18 (5), 261-279	2021
Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Emerging Burden S Batool, K Morton Cuthrell, N Tzenios, Z Shehryar International Research Journal of Oncology 6 (4), 93-104	2022
Modern therapeutic approaches for the treatment of malignant liver tumours H Petrowsky, R Fritsch, M Guckenberger, ML De Oliveira, P Dutkowski, ... Nature reviews Gastroenterology & hepatology 17 (12), 755-772	2020
Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma S D'souza, KCK Lau, CS Coffin, TR Patel World journal of gastroenterology 26 (38), 5759	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。